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httpObjective: To assess current knowledge for the management of ruptured abdominal aortic aneurysm (AAA),
based on the 1-year outcomes of 3 recent randomised trials.
Methods: An individual patient data meta-analysis of three recent randomised trials of endovascular versus open
repair, including 817 patients, was conducted according to a pre-speciﬁed analysis plan, report all-cause mortality
and re-interventions at 1 year after the index event.
Results: Mortality across the 3 trials at 1-year was 38.6% for the EVAR or endovascular strategy patient groups
and 42.8% for the open repair groups, pooled odds ratio 0.84 (95% CI 0.63e1.11), p ¼ .209. There was no
evidence of heterogeneity in the odds ratios between trials. When the patients in the endovascular strategy
group of the IMPROVE trial were restricted to those with proven rupture who were anatomically suitable for
endovascular repair, the pooled odds ratio reduced slightly to 0.80 (95% CI 0.56e1.16), p ¼ .240.
Conclusions: After 1 year there is a consistent but non-signiﬁcant trend for lower mortality for EVAR or an
endovascular strategy. Taken together with the recent gains in health economic outcomes demonstrated at 1
year in the IMPROVE trial, the evidence suggests that endovascular repair should be used more widely for
ruptured aneurysms.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The gold standard for surgical reporting standard is 30-day
mortality. The French ECAR trial, which reports in this
issue again shows that for ruptured abdominal aortic
aneurysm (AAA) 30-day mortality is similar after either
endovascular or open repair, echoing the recent AJAX and
IMPROVE trials and conﬁrmed in an individual patient
meta-analysis.1,2 For patients and health economies a
longer-term perspective is needed.3 Earlier this year the
IMPROVE trial reported outcomes to 1 year.4 There was no
statistically signiﬁcant difference in either overall mortality
or AAA-related mortality between the randomised groups,
although the estimate of overall mortality was numerically
slightly lower for the endovascular strategy group: 41%
versus 45% for open repair. ECAR also reports results to 1-
year, again with a survival estimate that is numerically lowerll list in Appendix 1.
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://dx.doi.org/10.1016/j.ejvs.2015.04.015for the endovascular repair group albeit with no statistically
signiﬁcant difference in survival.1
Collaboration between the AJAX, ECAR, and IMPROVE
trials (the Ruptured Aneurysm Trialists) also means that we
can investigate the hypothesis that the numerically higher
mortality in the open repair group of each trial would
summate to a signiﬁcant overall difference at 1 year after
randomisation. The results of this individual patient meta-
analysis are then discussed in the context of the total in-
formation available from the three trials.METHODS
The methods for the three trials included in this meta-
analysis have been published previously.6e8 The AJAX trial
(ISRCTN 66212637) randomised 116 patients, with a
computed tomography (CT) scan showing probable rupture
and patients being eligible for both open and endovascular
aneurysm repair (EVAR), in three centres between 2004
and 2011, using a software-generated randomisation
sequence provided by an independent clinical research
unit, concealed in sealed envelopes for a 1:1 randomisation
to either open or endovascular repair (aorto-uni-iliac grafts
for endovascular repair). The ECAR trial (NCT 0057716)
p 
p p 
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Figure 1. Survival to 1 year in the AJAX, ECAR, and IMPROVE randomised trials. The bottom right hand panel also shows data for the 308
IMPROVE trial patients with ruptured aorto-iliac aneurysm who were anatomically suitable for EVAR.
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conﬁrmed rupture and an aortic anatomy suitable for
endovascular repair and a systolic pressure of >80 mmHg,
with treatment allocation by weekly rotation, in 14 centres
between 2008 and 2012. The IMPROVE trial (ISRCTN
48334791) randomised 613 eligible patients with an in-
hospital clinical diagnosis of ruptured aneurysm in 29
centres between 2009 and 2013, using an independent
contractor providing telephone randomisation, with
computer-generated assignation of patients in a 1:1 ratio,
using variable block size and stratiﬁed by centre. For
IMPROVE, patients were randomised before CT scan, and
randomised to either an endovascular strategy (with open
repair if endovascular repair was not anatomically feasible)
or to open repair. All three trials were conducted with
appropriate ethical approvals; information about these
have been reported previously.6e8 The three data sets were
merged based on ﬁelds available in the case record forms
of the largest trial (IMPROVE), range checks were con-
ducted and queries resolved with the individual trial co-
ordinating centres.
Unfortunately the data from the pilot Nottingham trial9
could not be retrieved for the meta-analysis.Statistical analysis
The primary analyses considered the groups “as rando-
mised” within each trial, irrespective of the different trial
designs and assessed mortality at 1 year after random-
isation (for IMPROVE) and after admission (for AJAX and
ECAR). The odds ratio of mortality for the endovascular
strategy or EVAR versus open repair was estimated using
logistic regression adjusting for trial as described previ-
ously.2 Analyses were then repeated for odds ratiosestimated from logistic regression models adjusted for age,
sex, and Hardman index, a validated risk scoring system for
ruptured aneurysms.10 Patients lost to follow-up before 1-
year were excluded from these analyses. Secondary ana-
lyses were conducted with the purpose of making the
groups in the different trials more homogeneous. Only
those patients with a ruptured AAA ﬁnal diagnosis and
considered suitable for EVAR were retained in the analyses.
For AJAX and ECAR, suitability for EVAR was a prerequisite
for inclusion in the trial. For the IMPROVE trial suitability for
EVAR was deﬁned as either local CT assessment of suit-
ability or, if not assessed locally, a “within liberal In-
structions For Use” deﬁnition from a core laboratory CT
analysis was used.RESULTS
Summary KaplaneMeier curves for survival to 1 year for all
three trials are shown in Fig. 1. All trials show a small non-
signiﬁcant numerically higher mortality estimate after
open repair. The lower right-hand panel of Fig. 1 also
shows the summary survival by randomised group for
those patients from IMPROVE who had a conﬁrmed
rupture and were anatomically suitable for EVAR, a cohort
more similar to the AJAX and ECAR cohorts. At 1 year the
pooled mortality was 38.6% for EVAR/endovascular strat-
egy and 42.8% for open repair.
For survival at 1-year after admission or randomisation,
some patients had been lost to follow-up (AJAX 0, ECAR 17,
IMPROVE 2). The remaining 817 patients have been
included in an individual patient meta-analysis (Fig. 2A). The
evidence from all three trials is homogeneous and hints at a
slightly lower 1-year mortality after either EVAR or an
endovascular strategy, although the pooled odds ratio is not
Figure 2. Individual patient meta-analysis of 1-year mortality in AJAX, ECAR, and IMPROVE trials. (A) All patients as randomised. (B)
Patients with conﬁrmed rupture who were anatomically suitable for EVAR.
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The results are very similar after adjustment for age, sex,
and Hardman index. When the analysis was restricted to
consider only those patients who were considered
anatomically suitable for EVAR and had conﬁrmed rupture,
the results were similar but the pooled odds ratio estimate
now is slightly lower: 0.80 (95% CI 0.56 to 1.16), p ¼ .240
(Fig. 2B).
The major open surgical AAA-related re-interventions
which occurred between 30 days and 1 year are summar-
ised in Table 1: only the IMPROVE trial reports such re-
interventions in the open repair group. The reporting of
endovascular and non-AAA related re-interventions were
very different across the three trials and results cannot besummarised and therefore no formal meta-analysis of re-
intervention rates is possible.DISCUSSION
Open repair remains the most common intervention for
ruptured AAA.11,12 The early data from the randomised
trials did not suggest that there was any important survival
beneﬁt for EVAR versus open repair, but the individual pa-
tient meta-analysis showed some heterogeneity.2 At 1 year
the results are much more homogeneous and consistent,
although the small survival advantage for EVAR or an
endovascular strategy is not statistically signiﬁcant. These
results follow the publication of the 1-year results of the
Table 1. Aneurysm-related complications requiring open surgery between 30 days and 1 year.
Randomised group AJAX (n ¼ 116) ECAR followed to 1 year (n ¼ 90) IMPROVE
(n ¼ 500 ruptures followed to 1 year)
Open repair None reported None reported 7 (2 distal bypasses,
3 colonic resections
1 axillo-bifemoral graft)
EVAR/endovascular
strategya
2 conversions
(1 for graft infection)
4 (1 conversion for graft infection,
1 conversion for endograft thrombosis,
1 axillo-bifemoral bypass and
1 redo cross-over graft)
3 (1 distal bypass, 1 colonic resection,
1 conversion to open repair for
graft thrombosis)
a Endovascular strategy used in the IMPROVE trial as the randomised group to compare against Open repair.
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published results to 6 months 2 years ago.13
The ECAR trial did not assess full health economic out-
comes and patients were not followed up for quality of life.
The AJAX trial assessed health economic outcomes to 6
months only. The IMPROVE trial has now reported health
economic outcomes at 1 year and has identiﬁed gains for
the endovascular strategy group.4 For patients, full recovery
(discharge back to home with return to normal quality of
life, without any additional morbidity) is a key priority. The
IMPROVE trial showed that average hospital stay was 17
days in the endovascular strategy group and 26 days in the
open repair group and that at 3 months in the endovascular
strategy group more patients had returned home and had a
higher mean quality of life than in open repair group: re-
covery was faster in the endovascular strategy group.4 The
quality of life in the endovascular strategy group matched
that of UK patients undergoing elective aneurysm repair at
both 3 and 12 months.14 Moreover, there was no evidence
of a higher 1-year incidence of post-discharge AAA-related
re-interventions in the endovascular strategy group. These
ﬁndings translated into lower healthcare costs for the
endovascular strategy over the ﬁrst year following rupture,
and with the gains in quality of life there is emerging evi-
dence that an endovascular strategy is cost-effective in the
UK for ruptured AAA.4 Since, in sensitivity analyses, the
ﬁndings of the cost-effectiveness analysis were robust to a
variety of different assumptions including stafﬁng levels in
the operating theatre, the cost of devices, and including
non-AAA related hospital admissions and interventions, it is
likely that an endovascular strategy would also be cost-
effective in many other healthcare systems. This is
different from the ﬁndings of the Dutch AJAX trial,5 perhaps
because the IMPROVE trial included a much wider range of
patients (more representative of the total ruptured AAA
caseload).
If a new randomised trial was designed to show, with
90% power, that the 1-year mortality rate under EVAR was a
relative 20% lower than under open repair (assuming 40%
mortality under open and a 10% cross-over from both
groups), the trial would need approximately 2,500 patients
who were both anatomically suitable for EVAR and candi-
dates for open repair. For a cohort of patients, without
anatomical selection and a more modest mortality beneﬁt
for an endovascular strategy (relatively 15% lower thanunder open repair) a cohort of closer to 5,000 patients
would be needed. This is unlikely to happen for several
reasons. First the incidence of rupture is decreasing so if a
trial recruiting 600 patients (IMPROVE) was a major chal-
lenge, the challenge of a trial of 2,500e5,000 patients
would be even more formidable. The results for the trial
with the widest range of patients (IMPROVE) already sug-
gest patient beneﬁt and cost-effectiveness at 1 year. The
low re-intervention rate after emergency EVAR and cost-
effectiveness of an endovascular strategy at 1 year will
need conﬁrmation at 3 years before any new trials can be
fully informed: all three trials report a low rate of re-
interventions after EVAR in the ﬁrst year. Given the trends
from current results there might be limited equipoise and
enthusiasm for any new trials.
Perhaps more importantly, with gains for the endovas-
cular approach being indicated with longer-term follow up,
we need to identify how the results of endovascular repair
can be improved, through ﬂuid management, use of
endovascular occlusion balloons, local anaesthesia, and
other measures. It also is important to recognise that
outside the pioneering vascular centres, open repair will be
needed often for the 35e40% of patients who are not
suitable for conventional EVAR and therefore have an
intrinsically higher mortality risk.15,16
In summary, after three recent randomised trials and 1
year of patient follow-up the evidence suggests that
although endovascular repair does not offer a signiﬁcant
survival advantage, endovascular repair should be used
more widely. Nevertheless open repair must remain avail-
able for those unsuitable for conventional EVAR.
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AJAX Trial investigators
Academic Medical Center (39); R. Balm, M.J.W. Koelemay,
M.M. Idu, C. Kox, D.A. Legemate, L.C. Huisman, M.C.M.
Willems, J.A. Reekers, O.M. van Delden, K.P. van Lienden.
Trial coordinators: L.L. Hoornweg, J.J. Reimerink, S.C. van
Beek.
Onze Lieve Vrouwe Gasthuis (46); A.C. Vahl, V.J. Leijdek-
kers, J. Bosma, A.D. Montauban van Swijndregt, C. de Vries,
V.P.M. van der Hulst, J. Peringa, J.G.A.M. Blomjous, M.J.T.
Visser, F.H.W.M. van der Heijden
VU-University Medical Center (31); W. Wisselink, A.W.J.
Hoksbergen, J.D. Blankensteijn, M.T.J. Visser, H.M.E. Cove-
liers, J.H. Nederhoed, F.G. van den Berg, B.B. van der Meijs,
M.L.P. van den Oever, R.J. Lely, M.R. Meijerink,
Referring centres; Sint Lucas Andreas ziekenhuis; A.
Voorwinde, J.M. Ultee, R.C. van Nieuwenhuizen.
Slotervaartziekenhuis; B.J. Dwars, T.O.M. Nagy. BovenIJ
ziekenhuis; P. Tolenaar, A.M. Wiersema Ziekenhuis Amstel-
land; J.A. Lawson, P.J. van Aken, A.A. Stigter Water-
landziekenhuis; T.A.A. van den Broek, G.A. VosZaans
Medisch Centrum; W. Mulder, R.P. Strating Spaarne zie-
kenhuis; D. Nio, G.J.M. Akkersdijk, A. van der Elst
Regional ambulance services; P. van Exter
ECAR Trial investigators
CHU Henri Mondor: Prof. Pascal Desgranges, Prof. Jean-
Pierre Becquemin, Prof. Eric Allaire, Dr Cochennec, Dr
Marzelle (Dr Louis, Dr Schneider, Dr Majewski). CHU Bichat:
Prof. Yves Castier, Prof. Guy Leseche, Dr Fady Francis. CHU
Dijon: Prof. Eric Steinmetz, Dr Jean-Pierre Berne, Dr Claire
Favier.
CHRU Lille: Prof. Stephan Haulon, Prof. Mohammed
Koussa, Dr Richard Azzaoui, Dr D’elia Piervito. H.P. Marseille:
Prof Yves Alimi, Dr Mourad Bouﬁ, Dr Olivier Hartung, Dr
Pierre Cerquetta. CHU Marseille: Prof. Philippe Amabile,
Prof. Philippe Piquet, Dr Julien Penard, Dr Mariangela
Demasi. CHU Montpellier: Prof. Pierre Alric, Prof. Ludovic
Cannaud, Dr Jean-Pierre Berthet. CHU H.E.G.P.: Prof. Pierre
Julia, Prof. Jean-Nöel Fabiani, Dr Jean Marc Alsac. CHU
Brest: Prof. Pierre Gouny, Dr Ali Badra, Dr Jacques Braesco.
CHU Saint Etienne: Prof. Jean-Pierre Favre, Prof. Jean-Noel
Albertini. CHRU Tours: Dr Robert Martinez. CHU Nice:
Prof. Hassen-Khodja, Prof. Michel Batt, Dr Elixène Jean, Dr
Miguel Sosa, Dr Serge Declemy. CHR Annecy: Dr Laurence
Destrieux-Garnier. CHU Lyon: Prof. Patrick Lermusiaux, Prof.
Patrick Feugier.
IMPROVE trial investigators
Management Committee: Janet T. Powell (Chair), Ray
Ashleigh, Manuel Gomes, Roger M. Greenhalgh, Richard
Grieve, Robert Hinchliffe, Michael Sweeting, Matt M.
Thompson, Simon G. Thompson, Pinar Ulug.
United Kingdom: Nicholas J. Cheshire, Imperial College
Healthcare NHS Trust, London (20); Jonathan R. Boyle,
Addenbrooke’s Hospital, Cambridge (40); Ferdinand
Serracino-Inglott (J. Vince Smyth, Dec. 2012 to Nov. 2013),
Manchester Royal Inﬁrmary, Manchester (69); Matt M.Thompson, Robert J. Hinchliffe, St George’s Hospital, Lon-
don (75); Rachel Bell, Guy’s and St Thomas’ Hospital, Lon-
don (81); Noel Wilson, Kent and Canterbury Hospital,
Canterbury (23); Matt Bown (Dec. 2010 to present), Martin
Dennis (to Dec. 2010), Leicester Royal Inﬁrmary, Leicester
(18); Meryl Davis, Royal Free Hospital, London (1); Ray
Ashleigh, University Hospital of South Manchester, Man-
chester (21); Simon Howell, Leeds General Inﬁrmary, Leeds
(23); Michael G. Wyatt, Freeman Hospital, Newcastle (23);
Domenico Valenti, King’s College Hospital, London (2); Paul
Bachoo, Aberdeen Royal Inﬁrmary, Aberdeen (4); Paul
Walker, James Cook University Hospital, Middlesbrough (5);
Shane MacSweeney, Queen’s Medical Centre, Nottingham
(34); Jonathan N. Davies, Royal Cornwall Hospital, Truro (5);
Dynesh Rittoo (Jan. 2012 to present), Simon D. Parvin (to
Dec. 2011), Royal Bournemouth Hospital, Bournemouth
(22); Waquar Yusuf, Royal Sussex County Hospital, Brighton
(5); Colin Nice, Queen Elizabeth Hospital, Gateshead (5); Ian
Chetter, Hull Royal Inﬁrmary, Hull (32); Adam Howard,
Colchester General Hospital, Colchester (24); Patrick Chong,
Frimley Park Hospital, Surrey (14); Raj Bhat, Ninewells
Hospital, Dundee (8); David McLain, Royal Gwent Hospital,
Newport; Andrew Gordon (Jun. 2012- present), Ian Lane (to
Jun. 2012), University Hospital of Wales, Cardiff (4); Simon
Hobbs, New Cross Hospital, Wolverhampton (3); Woolaga-
sen Pillay, Doncaster Royal Inﬁrmary, Doncaster (8); Timothy
Rowlands (Nov. 2012-present), Amin El-Tahir (to Nov. 2012),
Royal Derby Hospital, Derby (13); John Asquith, University
Hospital of North Staffordshire, Stoke-on-Trent (15); Steve
Cavanagh, York Hospital, York (3); Canada: Luc Dubois (Sep.
2014-present), Thomas L. Forbes (to Aug. 2014), London
Health Sciences Centre, The University of Western Ontario,
London, ON (13).
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